HOME>Corporate Information>Corporate Data

Corporate Data

PDF file :
Corporate InformationPDF

Company Name
Mitsubishi Tanabe Pharma Corporation
Capital Stock
50 billion yen
President&Representative Director
Masayuki Mitsuka
3-2-10, Dosho-machi, Chuo-ku,
Osaka 541-8505, Japan
TEL: 81-6-6205-5085
December 13, 1933
Date of Merger
October 1, 2007
Business Activities


  • Manufacture and sale of pharmaceuticals, centered on ethical drugs
< Major Ethical Drugs >
Autoimmune disease

Remicade (agent for treatment of rheumatoid arthritis, Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis and ulcerative colitis)
Simponi (agent for treatment of rheumatoid arthritis)

Diabetes and kidney disease

Tenelia (agent for treatment of type Ⅱ diabetes mellitus)
Kremezin (agent for treatment of chronic renal failure)
Canaglu (agent for treatment of type Ⅱ diabetes mellitus)

CNS disease

Lexapro (anti-depressant agent)
Ceredist (agent for treatment of spinocerebellar degeneration)
Radicut (cerebral neuroprotectant)
Depas (anti-anxiety agent)

Other disease

Talion (agent for treatment of allergic disorders)
Maintate (agent for treatment of hypertension, angina pectoris, ventricular extrasystole, chronic heart failure and atrial fibrillation (tachycardiac)
Urso (agent for improvement of hepatic, biliary and digestive function)


TETRABIK (combined vaccine for diphtheria, pertussis, tetanus and poliomyelitis (polio) )
Varicella vaccine
JEBIK V (vaccine for Japanese encephalitis)
Mearubik(combined vaccine for measles and rubella)

< Major OTC Products >

Flucort f (agent for treatment of skin conditions)
Cort f series (agent for treatment of skin conditions)
Tanabe ichoyaku urso (digestive medicine)
Cerekinon S (digestive medicine)
Aspara drink α (oral solutions for tonic and nutritional supplement)
Nanpao (herbal medicine)